Azithromycin for early worsening of idiopathic pulmonary fibrosis
Treatments studied
Part of Lungs & breathing clinical trials.
This trial studies whether adding azithromycin to standard care can help people whose idiopathic pulmonary fibrosis is starting to flare up (worsen) in the early stages. It’s mainly for adults who are not very sick and cannot require intensive breathing support.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old
- Have an acute flare-up of idiopathic pulmonary fibrosis that is mild or early-to-moderate
- Have a score at or below 13 on the SCALE-IPF severity scale (as used in this study)
- Be able to receive study care through the Assiut University IPF research program (2022–2026)
- Not need a breathing machine or admission to an intensive respiratory care unit
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called zampilimab for people with idiopathic pulmonary fibrosis (IPF). It aims to find a safe and effective dose that may slow lung function decline.
This trial tests whether adding zinc and nicotinamide riboside (a vitamin B3-like supplement) to standard IPF treatment can help improve lung function. It is for people with IPF who are already seeing a lung doctor and live in certain states.
This trial tests a treatment that reduces certain antibodies in your blood, which may help slow the progression of IPF. The treatment involves a procedure to filter your blood and then giving you antibodies to help your immune system.
This study tests an inhaled medication for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if the drug is safe and how it works in the body. It might help by targeting the lungs directly with fewer side effects.
This study tests an experimental pill called SYH2059 for people with IPF, a condition that causes lung scarring and makes breathing harder. The goal is to see if the pill is safe and can help slow down the disease.
This Phase 3 study tests whether adding lansoprazole (a stomach acid medicine) can improve outcomes for people with idiopathic pulmonary fibrosis (IPF). You may already be on IPF “anti-fibrotic” medication, and the study checks if the added lansoprazole helps, compared with placebo.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.